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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effectiveness of fixed-dose combination therapy on optimising CVD risk factors and reducing CVD fatal and non-
fatal events for both primary and secondary prevention of CVD. Details of CVD events and risk factors included are listed in the
methods. We will also determine any adverse events associated with taking fixed-dose combination therapy. This will include studies
conducted in both developed and developing regions of the world.
B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is a principal cause of death world-
wide (WHO 2005). In 2008, it was directly responsible for more
than 17million deaths globally, over 80%ofwhich occurred in low
and middle-income countries (WHO 2010 (a)). Furthermore, the
situation is not expected to improve, with global CVD mortality
estimated to increase by six million over the next 20 years (WHO
2010 (a)). Ischaemic heart disease and cerebrovascular diseases -
themajor CVDs - are also major causes of disability resulting in 35
million disability-adjusted life years (DALYs) lost in 2004 (WHO
2004). Therefore, preventing deaths and disease due to CVD is a
priority for global public health.
CVD is a multi-factorial disease. Risk factors can be divided into
non-modifiable (including age and sex) and potentially modifi-
able. Worldwide case-control data demonstrate that in over 90%
of cases an individual’s first cardiovascular event relates to one or
more of ten specific modifiable factors, which include hyperten-
sion and abnormal lipid profile (O’Donnell 2010; Yusuf 2004).
Although the same risk factors are present in almost all popula-
tions, distribution has been shown to vary across regional and so-
ciological lines (Steyn 2005). Hypertension is most prevalent in
low and middle-income countries, whereas dyslipidaemia is most
prevalent in high-income countries (WHO 2010 (a)). In 2008,
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approximately 40% of UK adults as opposed to 45% of South
African adults older than 25 years had controlled or uncontrolled
hypertension. In contrast, in the same year, prevalence of hyper-
cholesterolaemia (total cholesterol greater than 5 mmol/L) in the
UK was 60% compared to 35% in South Africa (WHO 2008).
Almost 20% of adults older than 20 years have both hypertension
and dyslipidaemia in theUS (Wong 2006), and fewer than 10% of
US adults have nomajorCVDrisk factors (Ford 2009). Therefore,
modifiable risk factors are identifiable, prevalent in most popula-
tions, and often co-exist.
Optimising modifiable risk factors in an individual reduces overall
cardiovascular risk and thereby reduces CVD mortality and mor-
bidity (Cowie 2005). Individuals with both hypertension and dys-
lipidaemia have a greater risk of CVD than those with either hy-
pertension or dyslipidaemia alone (Neaton 1992; Thomas 2002),
highlighting the importance of considering overall CVDrisk as op-
posed to individual risk factors (Graham 2007). Therefore, adopt-
ing a multi-factorial approach to CVD risk management, where
multiple risk factors are modified simultaneously, is more effective
at reducing CVD events than focusing on single risk factors in
isolation (Gaede 2003).
Current national and international approaches to CVD preven-
tion incorporate both primary and secondary prevention (Graham
2007; NICE 2010). Primary prevention aims to prevent CVD
events in those who have no clinical evidence of CVD. To achieve
this, and using defined validated risk scores, guidelines recom-
mend intervening when the 10 year risk for any CVD event is
estimated to be at 20%, or when a fatal CVD event is estimated
to be at 5% (Graham 2007; NICE 2008; NICE 2010). Modify-
ing risk factors in this population is known to reduce CVD risk
and mortality by using antihypertensives to lower blood pressure
(Collins 1990) and statins to improve lipid profile (Taylor 2011).
Secondary prevention involves blood pressure control, cholesterol
lowering and use of antiplatelet drugs to prevent further CVD
events in those with pre-existing clinical evidence of CVD. This
approach is also known to be effective (ATT-Collaboration 2002;
Baigent 2005; Rashid 2003).
As the sameCVD risk factors operate throughout the global popu-
lation (Yusuf 2004), worldwideCVDprevention strategies need to
be multi-factorial. However, implementing conventional multi-
factorial CVD prevention approaches across the global popula-
tion, that is, targeting high risk individuals with various medica-
tions and regular monitoring to optimise multiple CVD risk fac-
tors, highlights three major issues:
(i) Epidemiological evidence suggests reducing blood pressure,
cholesterol and smoking each by 10% across the UK adult pop-
ulation would save over 9000 lives in 10 years (Cooney 2009),
significantly more than if a similar approach were targeted only
at high risk individuals (Cooney 2009). Therefore, a small reduc-
tion in cardiovascular risk across a large number of people may be
more effective at preventing CVD events in the population than
treating a small number of people at high risk (NICE 2010).
(ii) Lipid-lowering therapy in particular has been demonstrated
to reduce CVD events when pre-treatment lipid levels are normal
(Colhoun 2004; HPSCG 2002; O’Keefe 2004; Sever 2003). This
suggests that some with a potential to benefit from therapy may
be excluded under existing CVD prevention programmes.
(iii) Implementing the conventional CVD prevention strategy to
the whole population would be practically challenging, due to
the financial and time costs of monitoring, including the need
for regular blood samples, and the administration issues of mass
prescriptions of multiple tablets.
Therefore, because of the global burden of CVD and the issues
with implementing conventional strategies worldwide, an alterna-
tive and complementary population-wide strategy is required.
Description of the intervention
In 2001, a meeting of experts co-ordinated by the World Health
Organisation (WHO) and Wellcome Trust determined that the
use of a combination (fixed-dose) pill may be beneficial for sec-
ondary prevention of CVD (WHO 2002). A year later, Yusuf
proposed that a combination of four specific drugs (beta blocker,
aspirin, statin and ACE-inhibitor) could reduce CVD events by
75% in those already suffering from CVD (Yusuf 2002). In 2003,
Wald and Law first proposed their Polypill® (a combination of
folic acid, aspirin, three low-dose antihypertensives and a low-dose
statin) with the aim to reduce several cardiovascular risk factors
simultaneously (Wald 2003). They estimated that administration
to all with CVD (i.e. secondary prevention) as well as to all those
aged 55 years and over without CVD (i.e. modified primary pre-
vention) would safely reduce myocardial infarction by 88% and
stroke by 80% (Wald 2003). Recent evidence has indicated that
the effects of fixed-dose combination treatment may be less than
initially proposed, but that this strategy may improve blood pres-
sure and lipid profile to near expected levels (TIPS 2009), and
that in fact CVD event reduction of up to 50% by this route may
be feasible (PILL-collaborative 2011). The controversial aspect of
Wald and Law’s approach was the suggestion that the fixed-dose
combination therapy could be administered at a population level
without expensive screening of blood cholesterol or blood pressure
(Wald 2011). Instead a threshold age, such as above 55, would be
used as the entrance criterion (Lonn 2010; Wald 2003).
Recent evidence has supported aspirin for secondary prevention
but has questioned its use for primary prevention: the poten-
tial cost of serious bleeding may outweigh any CVD risk reduc-
tion benefit (Baigent 2009). Also, doubt exists regarding folic
acid, since recent large randomised trials indicated no CVD
benefit (Armitage 2010; Holmes 2011). On the other hand,
statins and antihypertensives as single treatments are known to
be relatively safe and beneficial individually in terms of reducing
CVD risk and thereby cardiovascular events for secondary pre-
vention and high-risk primary prevention (ALLHAT-investigators
2002; Colhoun 2004; HPSCG 2002; Julius 2004; Kearney 2008;
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LaRosa 2005; Ostergren 2008; Papademetriou 2003; Sever 2003;
Turnbull 2003). Therefore, although uncertainty exists regarding
possible components, the consensus is that the ideal fixed-dose
combination therapy for primary and secondary CVD prevention
should include at least one antihypertensive and one statin.
There is some recent evidence regarding efficacy and safety of
antihypertensives and statins when administered concomitantly
(Messerli 2006; Preston 2007), and of multiple antihypertensives
when administered as a single tablet (Gupta 2010).However, there
are concerns that clinicians may be wary of combination therapy,
due to the potential restrictions on individualised management
(Viera 2011); that is, the ability to amend standard therapy be-
cause of medical history or adverse events, such as avoiding a beta-
blocker in an asthmatic or changing from an ACE-inhibitor due
to cough, and to titrate each drug prescribed according to clinical
response (Lonn 2010).
How the intervention might work
According to the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) Working Group, how
strongly an intervention can be recommended to patients, clini-
cians and policymakers is determined by four factors: the balance
between beneficial and adverse effects, the quality of evidence,
the variability in preferences of those involved, and costs (Guyatt
2008). Pharmacological therapy has been postulated by some as
the population-level strategy with the most promise to reduce
global CVD risk (Beaglehole 2011; Lonn 2010). This is because
there is limited evidence of effectiveness regarding behavioural and
lifestyle interventions (Ebrahim 2011) and although modifying
national health policy has been successful in developed countries
such as Scandinavia (Vartiainen 2010), it is expensive and can be
politically challenging, especially in developing countries (Lonn
2010). However, the fixed-dose combination therapy is likely to
have a greater potential for adverse effects than behavioural or
lifestyle changes, and some argue that a purely biological approach
is too narrow to allow the social, economic and behavioural com-
plexities of CVD prevention to be appreciated and confronted
(Franco 2004).
Both statins and antihypertensives delivered separately or together,
reduce CVD risk and therefore CVD events in high risk pop-
ulations and in those with pre-existing CVD. However, despite
known effectiveness, not all those with a potential to benefit are
prescribed therapies (Kotseva 2009; Mendis 2005), and many are
non-concordant (Osterberg 2005). In some countries, therapies
cannot be afforded (Mendis 2005). Recent global epidemiological
data from the PURE investigators indicates that overall use of sec-
ondary prevention medication was less than 30%, and that levels
of use are particularly poor in low to middle-income countries
and in rural regions (Yusuf 2011). The likely result is inadequate
prevention of further CVD events.
There is a potential for these issues to be resolved by fixed-dose
combination therapy. Prescribing and administering a single tablet
to modify multiple risk factors simultaneously without the need
for intensive monitoring would be practical and desirable. Im-
plementing fixed-dose combination therapy for secondary pre-
vention of CVD is a much smaller extension from current prac-
tice, and so is less controversial. Most patients would already be
prescribed the individual components, and defining those with
a potential to benefit is far easier due to the presence of clinical
symptoms. However, two possibilities have been suggested for the
more contentious global fixed-dose combination therapy primary
prevention strategy: administer to the whole population above a
threshold age as suggested by the original Polypill® (Wald 2003;
Wald 2011), or administer to individuals identified as high risk
either with or without blood sample screening and monitoring
(Beaglehole 2011).Modified risk assessment charts have been pro-
duced for which blood samples are not necessary for risk stratifica-
tion (Gaziano 2008; WHO 2010 (b)). Using these charts to avoid
expensive screening andmonitoring, estimates suggest that a fixed-
dose combination therapy implemented across 23 low and mid-
dle-income countries solely to those identified as high risk would
cost approximately US$1 per person per annum (Lim 2007), an
amount likely to be affordable.
However, fixed-dose combination therapy still has many un-
knowns: (i) the best constituents: whether two or three or four or
five drugs are required and (ii) evidence of safety, effectiveness and
cost-effectiveness: whether increasing the number of constituents
will produce a favourable risk: benefit profile and be worth the in-
creased cost. In particular, the evidence is sparse concerning fixed-
dose combination therapy, both benefits and adverse effects, for
primary prevention in those with low CVD risk. Further knowl-
edge concerning this last point is essential if fixed-dose combi-
nation therapy is to be considered for administration to the en-
tire population above a threshold age. Finally, several authors have
questioned whether fixed-dose combination strategymay have un-
foreseen negative impacts on other aspects of CVD risk reduction
e.g. individuals neglecting to exercise because of a sense of CVD
security with fixed-dose combination therapy (Lonn 2010). As yet
there is no long-term follow-up outcome and safety data, which
is of particular concern considering that the original Polypill con-
cept was designed with long-term use of fixed-dose combination
therapy in mind.
Why it is important to do this review
Various fixed-dose combination pills are now in manufacture and
there is evidence that physicians are aware of this option and are
potentially willing to prescribe it (Viera 2011). There is an emerg-
ing literature of randomised controlled trials comparing fixed-dose
combination therapy with placebo or standard practice in both
primary and secondary prevention of CVD, as well as assessing
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safety and tolerability. However, to date, the evidence has not been
synthesised in a systematic review.
O B J E C T I V E S
To determine the effectiveness of fixed-dose combination therapy
on optimising CVD risk factors and reducing CVD fatal and non-
fatal events for both primary and secondary prevention of CVD.
Details of CVD events and risk factors included are listed in the
methods.Wewill also determine any adverse events associatedwith
taking fixed-dose combination therapy. This will include studies
conducted in both developed and developing regions of the world.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials.
Types of participants
Adults older than 18 years, with no restriction regarding presence
of CVD.
Types of interventions
A fixed-dose combination therapy: a combination of several active
components into a single pill with the aim to optimise CVD risk
and reduce CVD fatal and non-fatal events. At least one statin and
one antihypertensive agent should be included. Different combi-
nations and doses will be examined in stratified analyses if there
are sufficient trials.
Trials will be considered where the comparison group is standard
practice or placebo. Standard practice will vary between trials de-
pending on location of study. Proportion of participants under-
going existing treatment aimed at reducing CVD events or risk,
and specifics of treatment, will be noted.
Types of outcome measures
Primary outcomes
Clinical outcomes such asmortality (cardiovascular and all-cause);
non-fatal CVD endpoints such as myocardial infarction, coronary
artery bypass grafting (CABG), percutaneous transluminal coro-
nary angioplasty (PTCA), those with angina or angiographically
defined CHD, stroke, transient ischaemic attack (TIA), carotid
endarterectomy, peripheral arterial disease (PAD).
Secondary outcomes
Blood pressure (systolic and diastolic), lipid levels (total choles-
terol, high density lipoprotein (HDL), low density lipoprotein
(LDL) and triglycerides).
Health related quality of life, measured according to any well-
validated and adjusted scale concerning quality of life.
Adverse effects, including overall rates of discontinuation, propor-
tion of participants experiencing specific symptoms / results and
rates of discontinuation by specific symptoms / results (including
but not limited to: electrolyte disturbances, myalgia, elevated liver
enzymes). We will also consider adherence to therapy and any
changes in medication throughout the trials.
Costs of fixed-dose combination therapy.
Search methods for identification of studies
Electronic searches
The following electronic databases will be searched:TheCochrane
Library (including the Cochrane Central Register of Controlled
Trials (CENTRAL), DARE, HTA and NHS EDD), MEDLINE,
EMBASE and Web of Science. Medical subject headings (MeSH)
or equivalent and text word terms will be used. Searches will be
designed in accordance with Cochrane Heart Group methods and
guidance. There will be no language restrictions. The searches
have been limited to records published since 2000. The fixed-dose
combination therapy was conceptualised in 2001, and so relevant
trials will only appear after this date.
Searches will be tailored to individual databases. The search strat-
egy for MEDLINE is shown in Appendix 1.
Searching other resources
We will search the metaRegister of
controlled trials (mRCT) (www.controlled-trials.com/mrct), clin-
icaltrials.gov (www.clinicaltrials.gov) and theWHO International
Clinical Trials Registry Platform (ICTRP) (http://apps.who.int/
trialsearch/) for ongoing trials. In addition, reference lists of re-
views and retrieved articles will be checked for additional studies
and citation searches will be performed on key articles. Experts
in the field will be contacted for unpublished and ongoing trials.
Authors will be contacted where necessary for additional informa-
tion.
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Data collection and analysis
Selection of studies
From the searches, the title and abstract of each paper will be
reviewed by two reviewers and potentially relevant references re-
trieved. Following this initial screening, the full text reports of po-
tentially relevant studies will be obtained, and two reviewers (AdC
and MF) will independently select studies to be included in the
review using predetermined inclusion criteria. In all cases disagree-
ments about any study inclusions will be resolved by consensus
and a third reviewer will be consulted if disagreement persists.
Data extraction and management
Data will be extracted independently by two reviewers (AdC and
MF) using a proforma and chief investigators will be contacted
to provide additional relevant information if necessary. Details of
the study design, participant characteristics, study setting, inter-
vention and comparator, and outcome data including details of
outcome assessment, adverse effects and methodological quality
(randomisation, blinding, attrition) will be extracted from each
of the included studies. Disagreements about extracted data will
be resolved by consensus and a third reviewer will be consulted if
disagreement persists.
Assessment of risk of bias in included studies
Risk of bias will be assessed according to theCochrane Risk of Bias
Assessment tool, including examining the quality of the random
sequence generation and allocation concealment, description of
drop-outs and withdrawals (including analysis by intention-to-
treat), blinding (participants, personnel, and outcome assessment)
and selective outcome reporting (Higgins 2011). The risk of bias in
included studies will be assessed independently by two reviewers.
Measures of treatment effect
Data will be processed in accordance with the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). Di-
chotomous outcomes will be expressed as odds ratios or relative
risks, and 95% confidence intervals (CI) will be calculated for
each study. For continuous variables net changes will be compared
(i.e. intervention group minus control group differences) and a
weighted mean difference (WMD) or standardised mean differ-
ence (SMD) and 95% CIs will be calculated for each study.
Assessment of heterogeneity
For each outcome tests of heterogeneity will be carried out (using
the chi2 test of heterogeneity and I2 statistic). In the situation of
no heterogeneity a fixed-effect meta-analysis will be performed.
If substantial heterogeneity is detected the reviewers will look for
possible explanations for this (e.g. participants and intervention).
If the heterogeneity cannot be explained, the reviewers will con-
sider the following options: provide a narrative overview and not
aggregate the studies at all, or use a random-effects model with
appropriate cautious interpretation.
Subgroup analysis and investigation of heterogeneity
If there are sufficient studies we will conduct the following pre-
specified subgroup analyses:
1) Age.
2) Sex.
3) Focus of study is primary prevention (populations where 10%
or less have pre-existing CVD) versus secondary prevention (pop-
ulation where majority have pre-existing CVD).
4) High dose/potency of antihypertensive and statin used versus
lower dose. These are relative terms based on what is reported in
the included trials and do not relate to specific doses.
5) Two versus three or more fixed-dose drugs used.
Usual care will be as defined by the study. If applicable, results
within usual care group will be stratified and analysed separately.
Sensitivity analysis
Sensitivity analyses will be carried out excluding studies of low
methodological quality. Funnel plots and tests of asymmetry (
Egger 1997) will be undertaken to assess possible publication bias.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
MEDLINE OVID
The Cochrane sensitivity-maximising RCT filter has been used (Lefebvre 2011)
1. exp Cardiovascular Diseases/
2. cardio*.tw.
3. cardia*.tw.
4. heart*.tw.
5. coronary*.tw.
6. angina*.tw.
7. ventric*.tw.
8. myocard*.tw.
9. pericard*.tw.
10. isch?em*.tw.
11. emboli*.tw.
12. arrhythmi*.tw.
13. thrombo*.tw.
14. atrial fibrillat*.tw.
15. tachycardi*.tw.
16. endocardi*.tw.
17. (sick adj sinus).tw.
18. exp Stroke/
19. (stroke or stokes).tw.
20. cerebrovasc*.tw.
21. cerebral vascular.tw.
22. apoplexy.tw.
23. (brain adj2 accident*).tw.
24. ((brain* or cerebral or lacunar) adj2 infarct*).tw.
25. exp Hypertension/
26. hypertensi*.tw.
27. peripheral arter* disease*.tw.
28. ((high or increased or elevated) adj2 blood pressure).tw.
29. exp Hyperlipidemias/
30. hyperlipid*.tw.
31. hyperlip?emia*.tw.
32. hypercholesterol*.tw.
33. hypercholester?emia*.tw.
34. hyperlipoprotein?emia*.tw.
9Fixed-dose combination therapy for the prevention of cardiovascular disease (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
35. hypertriglycerid?emia*.tw.
36. or/1-35
37. Drug Combinations/
38. polypill*.tw.
39. (drug adj2 combin*).tw.
40. ((multi* or several) adj2 (ingredient* or component*)).tw.
41. policap.tw.
42. quintapill.tw.
43. (single adj2 pill* adj2 comb*).tw.
44. single-pill.tw.
45. Red Heart pill*.tw.
46. or/37-45
47 36 and 46
48. randomized controlled trial.pt.
49. controlled clinical trial.pt.
50. randomized.ab.
51. placebo.ab.
52. drug therapy.fs.
53. randomly.ab.
54. trial.ab.
55. groups.ab.
56. 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55
57. exp animals/ not humans.sh.
58. 56 not 57
59. 47 and 58
60. limit 59 to yr=“2000 -Current”
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